In patients with T2D, the risks for gastroesophageal reflux disease and related complications are greater with GLP-1 RA ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...

GLP-1 receptor agonists (RAs) are associated with fewer headaches and visual symptoms, reduced medication use, and less need for procedures — including bariatric surgery — compared with conventional ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a drug—taken in the form of a tablet—offers the outcome of ...

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient ...

More than twofold increased risk seen for nAMD development in unadjusted and adjusted models. HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 ...

Please provide your email address to receive an email when new articles are posted on . Many factors, not just rapid weight loss, influence facial appearance after GLP-1 treatment. Injectables and ...

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes ...